Pam R. Taub, MD, FACC, FASPC  

Podcasts

I'm sorry, but it seems there is no article text provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

Panelists discuss how lifestyle interventions, including diet, physical activity, and smoking cessation, complement pharmacotherapy in the management of dyslipidemia, and explore unmet needs in cardiovascular risk reduction, highlighting the role of emerging therapies such as bempedoic acid, inclisiran, and gene editing technologies.

Navigating Lifestyle and Pharmacotherapy Interventions in Dyslipidemia Management  

Exploring Bempedoic Acid: Clinical Indications, Efficacy, and Future Directions in Cardiovascular Risk Management 

Panelists discuss how bempedoic acid offers a promising alternative for patients who are statin-intolerant, demonstrating efficacy in reducing major cardiovascular events and low-density lipoprotein cholesterol, while addressing its role in managing residual cardiovascular risk, particularly in high-risk populations.

Pam R. Taub, MD, FACC, FASPC

Articles